Related Experiment Videos
P-Glycoprotein, Multidrug Resistance and Protein Kinase C.
1Experimental Therapeutics Section, Division of Medical Oncology, Columbia University, College of Physicians and Surgeons, New York, New York, 10032, USA.
The Oncologist
|January 1, 1996
Summary
Protein kinase C (PKC) activity correlates with multidrug resistance (MDR) in cancer. Further research is needed to confirm if PKC directly impacts P-glycoprotein function in MDR.
Area of Science:
- Biochemistry
- Cancer Biology
- Molecular Pharmacology
Background:
- Multidrug resistance (MDR) is a significant challenge in cancer therapy.
- P-glycoprotein is a key mediator of MDR, but its regulation is not fully understood.
- Protein kinase C (PKC) has been observed to correlate with the MDR phenotype.
Purpose of the Study:
- To review the literature on the role of PKC in MDR.
- To investigate the potential impact of PKC-mediated phosphorylation on P-glycoprotein function.
- To identify areas requiring further investigation regarding PKC and MDR.
Main Methods:
- Literature review of studies investigating PKC and MDR.
- Analysis of evidence linking PKC activity to P-glycoprotein expression and function.
- Discussion of biochemical mechanisms, including phosphorylation, and anti-apoptotic pathways.
Main Results:
- Increased PKC activity is frequently associated with the MDR phenotype, particularly in doxorubicin-selected cells.
- PKC isoenzymes may differentially phosphorylate P-glycoprotein, potentially altering its ATPase and drug-binding functions.
- PKC's role in anti-apoptotic pathways complicates the study of drug resistance mechanisms.
Conclusions:
- A direct modulatory role of PKC on P-glycoprotein function in MDR remains to be definitively established.
- Further studies are required to elucidate the precise mechanisms by which PKC influences P-glycoprotein and contributes to MDR.
- Understanding these interactions is crucial for developing strategies to overcome drug resistance in cancer.